Publication & Citation Trends
Publications
0 total
Abstract 6761: Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts
Cited by 0
Semantic Scholar
Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.
Cited by 0
Semantic Scholar
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Cited by 1
Semantic Scholar
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer OA
Cited by 1
Semantic Scholar
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models OA
Cited by 1
Semantic Scholar
Abstract 6180: Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterations
Cited by 0
Semantic Scholar
Abstract P5-08-12: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations
Cited by 0
Semantic Scholar
Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations
Cited by 1
Semantic Scholar
Research Topics
Cancer Mechanisms and Therapy
(15)
Nuclear Receptors and Signaling
(15)
HER2/EGFR in Cancer Research
(8)
Chromatin Remodeling and Cancer
(8)
Advanced Breast Cancer Therapies
(8)
Affiliations
The University of Texas MD Anderson Cancer Center